Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts Authors: Charles Terra, Olivier Terrier, Audrey Le Gouellec Published: 2026 ABSTRACT AbstractBackgroundSARS-CoV-2 and Influenza virus are two major respiratory viruses, responsible for the COVID-19 and the flu respectively. To achieve their replication, these viruses do not merely hijack host cells; they reprogram them, and the host’s metabolism is no exception.Aim of the reviewThis review explores how two major respiratory pathogens, SARS-CoV-2 and influenza virus, manipulate host metabolism to fuel their replication and drive disease.Key scientific concepts of the reviewDespite differences in their genome organization and replication strategies, both viruses disrupt central metabolic pathways, including glucose processing, the Krebs cycle, amino acid and nucleotide synthesis. Common effects include enhanced anaerobic glycolysis, depletion of key amino acids, activation of the kynurenine pathway, and disruption of purine signaling. However, each virus leaves a distinct metabolic fingerprint. SARS-CoV-2 infection leads to glucose accumulation, alters late-stage Krebs cycle metabolites, and significantly disrupts nucleotide production. In contrast, influenza viral infection depletes glucose and dampens Krebs cycle activity, with a less consistent impact on nucleotide pathways. Viral proteins, such as SARS-CoV-2 ORF3a and influenza virus NS1, play a crucial role in these metabolic shifts. These changes not only reflect viral strategies but also correlate with disease severity. As metabolomics technologies advance, understanding these virus-specific and shared metabolic changes could unlock new diagnostic tools, prognostic markers, and treatment strategies.Keywords: Influenza virus, SARS-CoV-2, COVID-19, Host metabolism, Virus-host interactions Introduction By their nature, viruses hijack their host cell machinery to support their replication. Metabolism involves molecules that are important for cell function and signaling and is, therefore, a prime target for viruses. Nearly all viruses can reprogram host cell metabolism to their advantage, which can induce an increase in the production of macromolecules needed for their replication or influence immune cell functions (Thaker et al., 2019). Among viruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses (IV) are major respiratory pathogens responsible for the coronavirus disease 2019 (COVID-19) pandemic and seasonal flu epidemics, respectively. Both viruses differ regarding their genomes, entry factors, and viral cycles (Fig. 1). In particular, the main viral receptor for SARS-CoV-2 is the angiotensin-converting enzyme 2 (ACE2) involved in the metabolism through the renin-angiotensin system. Despite those differences, SARS-CoV-2 and IV induce infections with varying severities according to patients, ranging from asymptomatic to acute respiratory distress syndrome or even death. Similarities can also be found in early symptoms that are often confused, as well as in associated risk factors, including metabolic diseases such as obesity or diabetes (Flerlage et al., 2021), highlighting the importance of host metabolism in the pathophysiology of both COVID-19 and influenza. Replication cycles of SARS-CoV-2 and influenza virus (IV). SARS-CoV-2 enters host cells through ACE2 binding and either TMPRSS2-mediated fusion or endocytosis, followed by genome release. Viral RNA is translated into polyproteins processed into nonstructural proteins, including the RNA polymerase, which drives replication and transcription in double-membrane vesicles. Structural and accessory proteins are produced, with the latter modulating host responses, while new virions assemble in the ERGIC and are released by exocytosis. For IV, infection starts with HA binding to sialic acids and viral uptake by endocytosis. vRNPs are released, imported into the nucleus, and used for replication and transcription. Viral mRNAs are translated, structural proteins inserted into the membrane, and vRNPs exported via recycling endosomes. Assembly occurs at the plasma membrane, where budding generates new virions. The figure was created with BioRender.com Like other viruses, SARS-CoV-2 and IV disrupt the metabolism of their host cells. A better understanding of host responses to these infections may enable the identification of specific biomarkers that can support diagnosis and help predict which patients are at risk of severe outcomes. Furthermore, a deeper understanding of the mechanisms and significance of these metabolic disruptions in SARS-CoV-2 and IV infections may facilitate the identification of new therapeutic targets, thereby paving the way for the development of innovative treatment strategies. Whilst several reviews have examined the effects of infection with these two viruses on the host’s metabolism separately, few have conducted a systematic comparison between these two major pathogens. This review describes the metabolic disruptions that occur during infections with SARS-CoV-2 and influenza viruses. We focus on four key metabolic pathways, including glucose metabolism, the Krebs cycle, amino acid (AA) metabolism, and nucleotide metabolism, because of their central roles in cellular energy production, biosynthesis, and immune regulation, all of which are frequently reprogrammed by viruses to promote their replication and survival. The structure of the review is as follows: for each of these pathways, we first summarize the reported alterations induced by SARS-CoV-2 infection, then present the corresponding data available for influenza virus infection. Finally, we provide a comparative synthesis that highlights both the common features and the distinct differences in host metabolic responses to these two viral infections. Glucose: a central node in viral metabolic reprogramming Glucose serves as the primary energy and carbon source for cells, fueling glycolysis to generate pyruvate, which is subsequently utilized in mitochondria to produce adenosine triphosphate (ATP). Additionally, glucose-derived carbons contribute to AA biosynthesis as well as to the pentose phosphate pathway, which supports nucleotide synthesis and cellular redox balance (Mulukutla et al., 2016). Glycolysis consists of three key phases: (1) glucose phosphorylation, leading to fructose 1,6-bisphosphate formation, (2) conversion of fructose 1,6-bisphosphate into triose phosphates, and (3) generation of ATP through the conversion of triose phosphates into pyruvate (Fig. 2). The metabolic fate of pyruvate depends on oxygen availability; under anaerobic conditions, it is reduced to lactate, requiring monocarboxylate transporters for efflux, whereas in the presence of oxygen, pyruvate enters the Krebs cycle for oxidative phosphorylation (Fig. 2). Schematic representation of major central metabolic pathways, including glycolysis (red), the pentose phosphate pathway (light red), the Krebs cycle (light blue), amino acid metabolism (purple), the urea cycle (yellow-green), tryptophan metabolism (blue-green), and purine/pyrimidine biosynthesis (dark blue). Key enzymes are indicated in each pathway. Glycolysis, HK : Hexokinase, GPI : Glucose-6-phosphate isomerase, PFKA : ATP-dependent 6-phosphofructokinase, ALDO : Fructose-bisphosphate aldolase, TPI1 : Triosephosphate isomerase, GAPDH : Glyceraldehyde-3-phosphate dehydrogenase, PGK1 : Phosphoglycerate kinase 1, PGAM1 : Phosphoglycerate mutase 1, ENO : Enolase, PKM : Pyruvate kinase PKM, LDH : L-lactate dehydrogenase; AA : Glycolysis, PHGDH : D-3-phosphoglycerate dehydrogenase, PSAT1 : Phosphoserine aminotransferase, PSPH : Phosphoserine phosphatase, SHMT1 : Serine hydroxymethyltransferase, MAT : S-adenosylmethionine synthase, MTs : Methyltransferases, AHCY : Adenosylhomocysteinase, CBS : Cystathionine beta-synthase, CTH : Cystathionine gamma-lyase; Krebs cycle, PDHc : Pyruvate deshydrogenase complex, PC : Pyruvate carboxylase, CS : Citrate synthase, ACO2 : Aconitase 2, IDH3/2 : Isocitrate dehydrogenase 3/2, OGDH : Oxoglutarate dehydrogenase complex, SCS : Succinyl-CoA synthetase, SDH : succinate dehydrogenase, FH : Fumarate hydratase, MDH2 : Malate dehydrogenase 2; AA : Krebs cycle, GLUD1 : Glutamate dehydrogenase 1, GPT : Alanine aminotransferase 1, GOT1 : Aspartate aminotransferase, ALDH18A1 : Delta-1-pyrroline-5-carboxylate synthase, PYCR : Pyrroline-5-carboxylate reductase, OAT : Ornithine aminotransferase, ASNS : Asparagine synthetase, GLUL : Glutamine synthetase, OTC : Ornithine transcarbamylase, ASS1 : Argininosuccinate synthase, ASL : Argininosuccinate lyase, ARG : Arginase; Tryptophane pathway, IDO : Indoleamine 2,3-dioxygenase, TDO2 : Tryptophan 2,3-dioxygenase, AFMID : Kynurenine formamidase, KYAT : Kynurenine–oxoglutarate transaminase, KMO : Kynurenine 3-monooxygenase, KYNU : Kynureninase, ACMSD : 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase, HAAO : 3-hydroxyanthranilate 3,4-dioxygenase, QPRT : Nicotinate-nucleotide pyrophosphorylase, NMNAT : Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, TPH : Tryptophan 5-hydroxylase, DDC : Aromatic-L-amino-acid decarboxylase, AANAT : Serotonin N-acetyltransferase, ASMT : Acetylserotonin O-methyltransferase; Pentose phosphate pathway, TKT : Transketolase, G6PD : Glucose-6-phosphate 1-dehydrogenase, PGLS : 6-phosphogluconolactonase, PGD : 6-phosphogluconate dehydrogenase, decarboxylating, RPE : Ribulose-phosphate 3-epimerase, RPIA : Ribose-5-phosphate isomerase; Purines, PRPS : Ribose-phosphate pyrophosphokinase, PPAT : Amidophosphoribosyltransferase, GART : Trifunctional purine biosynthetic protein adenosine-3, PFAS : Phosphoribosylformylglycinamidine synthase, PAICS : Bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase, ADSL : Adenylosuccinate lyase, ATIC : Bifunctional purine, biosynthesis protein, ADSS2 : Adenylosuccinate synthetase isozyme 2, AK : Adenylate kinase, IMPDH : IMP dehydrogenase, GMPS : GMP synthase, GUK1 : Guanylate kinase, NME : nucleoside-diphosphate kinase, APRT : Adenine phosphoribosyltransferase, ADK : Adenosine kinase, PNP : Purine nucleoside phosphorylase, ADA : Adenosine deaminase, NT5 : 5‘(3’)-deoxyribonucleotidase, HPRT : Hypoxanthine phosphoribosyltransferase, GDA : Guanine deaminase, XO : Xanthine oxidase; Pyrimidine, CPS1 : Carbamoyl-phosphate synthase, CAD : Multifunctional protein CAD [carbamoylphosphate synthetase (CPSase; EC 6.3.5.5), aspartate transcarbamylase (ATCase; EC 2.1.3.2) and dihydroorotase (DHOase; EC 3.5.2.3)], DHODH : Dihydroorotate dehydrogenase, UMPS : Uridine 5’-monophosphate synthase, CMPK : UMP-CMP kinase, NDK6 : Nucleoside diphosphate kinase 6, UCK1 : Uridine-cytidine kinase 1, CTPS : CTP synthase, ENTPD1 : Ectonucleoside triphosphate diphosphohydrolase 1, CDA : Cytidine deaminase, UPP1 : Uridine phosphorylase 1, RRM : Ribonucleoside-diphosphate reductase, DTYMK : Thymidylate kinase, TYMP : Thymidine phosphorylase, DPYP : Dihydropyrimidine dehydrogenase, UPB1 : Beta-ureidopropionase Many viral infections hijack cellular metabolism by upregulating glycolysis to support viral replication. For instance, respiratory syncytial virus induces a shift in glycolytic metabolism via the Hypoxia-inducible factor 1 (HIF-1) stabilisation, channelling intermediates into anabolic pathways for the biosynthesis of AA, nucleotides, and lipids, which are required for genome replication, messenger RNA (mRNA) transcription, viral protein synthesis, and envelope formation. Moreover, glycolysis contributes to ATP production, providing the necessary energy for efficient viral replication (Kleinehr et al., 2021). Metabolic reprogramming of glucose pathways in favour of anaerobic glycolysis during SARS-CoV-2 infection SARS-CoV-2 increases anaerobic glycolysis (Fig. 3A). Indeed, SARS-CoV-2 infection induces a significant increase in multiple glycolysis metabolites, ranging from glucose to lactate, in human blood samples (Bruzzone et al. 2020; Caterino et al. 2021; Escarcega et al. 2022; Herrera-Van Oostdam et al. 2021; Jia et al. 2022; Krishnan et al. 2021; Lee et al. 2024; Lodge et al. 2023; Meoni et al. 2021; Saheb Sharif-Askari et al. 2022; Shi et al. 2021; Thomas et al., 2020a, 2020b; Whiley et al. 2024). Interestingly, higher disease severity correlates with greater increases in glucose and lactate levels, underscoring the link between metabolic disruption and disease severity (Caterino et al. 2021; Karagiannis et al. 2022). This metabolic shift, characterized by enhanced anaerobic glycolysis, resembles the Warburg effect classically observed in cancer cells and also reported in viral infections (Sanchez and Lagunoff 2015). The Warburg-like metabolic reprogramming in SARS-CoV-2 infection is mediated by the PI3K/Akt/mTORC1/HIF-1 (Phosphatidylinositol 3-kinase; RAC serine/threonine-protein kinase; mammalian target of rapamycin complex 1) and RAF/MEK/ERK (Rapidly Accelerated Fibrosarcoma; Dual specificity mitogen-activated protein kinase kinase; extracellular signal-regulated kinases) mitogen-activated protein kinase (MAPK) pathways (Engler et al. 2023; Mullen et al. 2021), leading to the upregulation of glycolytic enzymes and glucose transporters (Duan et al. 2021; Krishnan et al. 2021). Indeed, SARS-CoV-2 S protein has been shown to enhance Akt phosphorylation (Al-Qahtani et al. 2022) and activate MAPK signaling (Engler et al. 2023). Another SARS-CoV-2 protein, ORF3a (origin of replication 3a), was demonstrated to promote HIF-1 through the induction of mitochondrial-derived reactive oxygen species (Tian et al. 2021). Moreover, this activation of the Warburg effect appears essential for SARS-CoV-2 infection as the inhibition of the PI3K/Akt/mTORC1/HIF-1 or RAF/MEK/ERK axis impairs SARS-CoV-2 replication or infection, respectively (Duan et al. 2021; Engler et al. 2023). Impact of SARS-CoV-2 and influenza virus (IV) infections on central metabolic pathways. A Overview of SARS-CoV-2–induced changes in glycolysis, the Krebs cycle, amino acid, and nucleotide metabolism. B Overview of IV-induced changes in the same pathways. In (A, B), increased metabolite levels in comparison to non-infected condition are shown in red, and decreased ones in blue. Solid lines indicate direct products, dotted lines indirect ones Remodelling of glucose pathways towards anaerobic glycolysis during influenza virus infection IV infection also increases anaerobic glycolysis (Fig. 3B). Contrary to patients with COVID-19, glucose level seems to decrease after IV infection (Lee et al., 2024; Liempd et al., 2021), with a stronger reduction associated with a more severe disease (Izquierdo-Garcia et al., 2018). Conversely, pyruvate and lactate levels at the end of the pathway are increased in both patient samples and in vivo models (Banoei et al., 2017; Beale et al., 2021; Cui et al., 2016; Lee et al., 2024). The increase in pyruvate is even more significant in patients who will die from the flu (Banoei et al., 2017), suggesting that infection progression is associated with a pronounced impact on host glycolysis. The decrease in starting metabolites and the increase in ending ones suggest that glycolysis is upregulated after IV infection, predominantly anaerobic glycolysis. The impact of IV infection on host glycolysis is similar to that of the Warburg effect, with the main pathways involved being strongly impacted during infection. Indeed, the PI3K/Akt/mTORC1/HIF-1 and RAF/MEK/ERK pathways are activated during the time-course of infection, especially through the viral non-structural protein NS1 (Dai et al., 2011). SARS-CoV-2 and influenza virus infections induce a shift in glucose metabolism toward increased anaerobic glycolysis SARS-CoV-2 and IV infections lead to the accumulation of end-glycolysis products, such as pyruvate and lactate, reflecting anaerobic glycolysis. These glycolysis products can enter other anabolic pathways or be used for nicotinamide adenine dinucleotide (NAD) and ATP production, supporting viral replication. Both viruses induce glycolysis gene upregulation by activating the PI3K/Akt/mTORC1/HIF-1 and RAF/MEK/ERK pathways. However, a significant difference lies in the accumulation of glucose after SARS-CoV-2 infection, in contrast to what is observed during infection with IV. The Krebs cycle: fueling and regulating viral infection The Krebs cycle is an amphibolic pathway that occurs in the mitochondria of aerobic organisms. It represents the final step in carbohydrate, protein, and lipid oxidation, generating approximately two-thirds of cellular ATP. Beyond energy production, the Krebs cycle provides important key intermediates for biosynthetic pathways, AA and fatty acids biosynthesis. Moreover, Krebs cycle metabolites are involved in immunity, either with pro- or anti-inflammatory roles(Bei et al., 2023; Claus & Liebert, 2014; Sánchez-García et al., 2021). The cycle is initiated by the condensation of Acetyl-Coenzyme A (CoA) and oxaloacetate to form citrate, catalysed by citrate synthase. Acetyl-CoA is generated from pyruvate, AA metabolism, or fatty acid oxidation, while oxaloacetate is regenerated in the final step of the cycle. The Krebs cycle consists of eight enzymatic steps, spanning from citrate formation to oxaloacetate regeneration (Martínez-Reyes & Chandel, 2020) (Fig. 2). Viruses employ different strategies to modulate host metabolism: to fuel the Krebs cycle, the Human herpes simplex virus 1 infection enhances glycolysis, whereas efficient Human adenovirus C serotype 2 infection relies on glutaminolysis (Claus & Liebert, 2014; Sánchez-García et al., 2021). Conversely, hepatitis B virus infection tends to reduce Krebs cycle activity (Bei et al., 2023). The importance of the Krebs cycle in many metabolic pathways and its involvement in inflammation may explain its central role in the biology of many viruses. SARS-CoV-2 infection decreases the levels of early Krebs cycle intermediates while leading to an accumulation of metabolites downstream of alpha-ketoglutarate Metabolites from the early stage of the Krebs cycle, spanning from oxaloacetate to isocitrate, have been found to have reduced levels in blood samples from COVID-19 patients (Albóniga et al. 2022; Escarcega et al. 2022; Herrera-Van Oostdam et al. 2021; Krishnan et al. 2021; Lee et al. 2024; Meoni et al. 2021; Páez-Franco et al. 2021; Saheb Sharif-Askari et al. 2022; D. Shi et al. 2021). Notably, the observed decrease of citrate correlates with disease severity, indicating that Krebs cycle disruption may contribute to COVID-19 severity (Herrera-Van Oostdam et al. 2021). In contrast, metabolites from later stages of the cycle, from alpha-ketoglutarate to malate, are elevated in blood and even saliva samples from COVID-19 patients (Fig. 3A) (Barberis et al. 2020; Bruzzone et al. 2020; Caterino et al. 2021; D’Alessandro et al. 2021; Escarcega et al. 2022; Giron et al. 2021; Jia et al. 2022; Lee et al. 2024; Páez-Franco et al. 2021; Saheb Sharif-Askari et al. 2022; D. Shi et al. 2021; Thomas et al. 2020a, 2020b; Whiley et al. 2024). Interestingly, succinate accumulation was shown to be more pronounced in patients with severe disease (Giron et al. 2021). Moreover, patients in the recovery phase exhibit a decrease in malate levels compared to actively infected individuals, underlying a potential return of Krebs cycle metabolism to a homeostatic state post-infection (Jia et al. 2022). During SARS-CoV-2 infection, Mullen et al. showed using in vitro models that glycolysis provides a source of carbon to the Krebs cycle through a higher pyruvate influx, driven by the upregulation of pyruvate carboxylase (Mullen et al. 2021). Conversely, SARS-CoV-2 infection activates sirtuin (SIRT) 5 activity through its interaction with the viral protein Ns14, reducing the entry of pyruvate into the Krebs cycle (Fabbrizi et al. 2023). It has also been underlined that the Krebs cycle is supported by glutaminolysis during SARS-CoV-2 infection (Krishnan et al. 2021). Moreover, genes involved in various steps of the Krebs cycle are downregulated following SARS-CoV-2 infection (S. Li et al. 2023), including key enzymes directly inhibited by SIRT5 (Fabbrizi et al. 2023). While metabolites from the early stages of the Krebs cycle decrease, those from later stages accumulate after SARS-CoV-2 infection. This suggests that, despite downregulation of Krebs cycle-associated genes, the cycle remains active, likely supporting energy production, Amino acid and pyrimidine biosynthesis through increased carbon influx from glycolysis. The induction of glutaminolysis could explain the duality in Krebs cycle disruption induced during SARS-CoV-2 infection. Most of the Krebs cycle metabolites are reduced during influenza viral infection A significant portion of Krebs cycle metabolites exhibits decreased levels following IV infection, as indicated by studies conducted on patient samples and in vivo models (Fig. 3B) (Beale et al., 2019; Cui et al., 2017; Lee et al., 2024; Liempd et al., 2021; Ohno et al., 2020). Interestingly, α-ketoglutarate levels are significantly lower in patients who do not survive than in survivors (Banoei et al., 2017), suggesting a link between disease severity, this metabolite, and possibly the Krebs cycle. Succinate also appears to be disease progression-dependent, as its levels increase during the early stage of infection before subsequently declining (Ohno et al., 2020). Moreover, succinate accumulation has been observed in tracheal respirate of critically infected patients, which could be a part of the host antiviral strategy as succinylation of NP is associated with a defect in vRNPs assembly (Guillon et al., 2022). Notably, no significant disruptions in succinyl-CoA or oxaloacetate levels have been found in the literature. Conversely, in vitro models have shown an increase in isocitrate and cis-aconitate levels. However, this study also found increases in other Krebs cycle metabolites (Ritter et al., 2010), showing that the impact of IV on the Krebs cycle is highly dependent on the experimental model used. Ohno et al. proposed that this reduction in Krebs cycle flux is linked to a decrease in substrate amounts (Ohno et al., 2020), which supports the increase in anaerobic glycolysis. The increase in pyruvate dehydrogenase kinase 3 expression following IV infection goes in that way as it lead to pyruvate dehydrogenase inhibition (Ren et al., 2021). Moreover, the SIRT1 and SIRT2, which promote Krebs cycle activity (Zhu et al., 2019), have reduced expression in infected A549 cells and patient samples, respectively (De Angelis et al., 2022; Yuan et al., 2023). While influenza virus infection induces a decrease in compounds of the whole Krebs cycle, SARS-CoV-2 only reduces metabolite of its first part, and increase most of the others SARS-CoV-2 and IV infection induce a decrease in many Krebs cycle metabolites, especially the early ones, which an increased usage of alpha-ketoglutarate to produce glutamate could explain. Moreover, infection by one virus or the other leads to the downregulation of key genes involved in the Krebs cycle, which underlies virus-induced mitochondrial defects. However, the accumulation of metabolites from alpha-ketoglutarate to malate appears to be specific to SARS-CoV-2 infection. Amino acid pathways: building blocks for viral replication Amino Acids serve as protein building blocks, play the role of biomolecule precursors, and can be used to generate ATP, glucose, and fatty acids. In animals, nine “essential” AA can’t be synthesized and need to be provided by nutrition. The eleven others are considered “non-essential” and are primarily derived from glycolysis or the Krebs cycle, but can also be obtained from food (Chandel, 2021). Glycolysis through 3-phosphoglycerate is at the origin of serine, glycine, and cysteine. The latter also necessitates homocysteine, a precursor derived from the essential AA methionine (Chandel, 2021). The Krebs cycle metabolite alpha-ketoglutarate can be metabolized into glutamate, which is at the origin of a few AA, namely alanine, aspartate, glutamine, asparagine, proline, and arginine in the urea cycle (Chandel, 2021). The essential AA tryptophan is at more than 95% metabolised into the kynurenine pathway by the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, but it is also at the origin of the serotonin and melatonin biosynthesis pathway. Interestingly, IDO1 is linked to inflammation through its activation by inflammatory receptors such as the interferon-gamma receptor or the toll-like receptor 4, leading to enhanced energy production, via NAD+ biosynthesis (Chandel, 2021; Xu et al., 2024). Moreover, IDO1 also induces immunomodulation and ACE2 expression by translocating the aryl hydrocarbon receptor to the nucleus (Xu et al., 2024). The remaining AA are essential and don’t participate in central metabolic pathways, except for tyrosine, which can be biosynthesized by consuming phenylalanine and plays a role as a precursor in the dopamine and epinephrine biosynthesis pathway (Chandel, 2021) (Fig. 2). Viral replication requires higher protein production and, therefore, an increase in AA consumption. As shown previously, glutamine is also used in glutaminolysis to fuel the Krebs cycle. Moreover, many viruses, including the Human immunodeficiency virus and West Nile virus, induce a depletion of tryptophan and an increase in kynurenine, which is associated with inhibition of the host immune response (Kleinehr et al., 2021; Xu et al., 2024). SARS-CoV-2 infection alters host amino acid metabolism, typically reducing amino acid (AA) levels while promoting activation of the kynurenine pathway AAs derived from glycolysis exhibit mixed trends, with some studies reporting increases (Caterino et al. 2021; T. Li et al. 2021; D. Shi et al. 2021; J. Wu et al. 2021) and others reporting decreases (Albóniga et al. 2022; D’Alessandro et al. 2021; Karagiannis et al. 2022; Masoodi et al. 2022; Páez-Franco et al. 2021; Thomas et al., 2020b). Glycine level consistently decreases (Essex et al. 2024; Karagiannis et al. 2022; Lee et al. 2024; Masoodi et al. 2022; Meoni et al. 2021; Thomas et al., 2020b). Methionine and homocysteine levels decline, while S-adenosyl-methionine and S-adenosyl homocysteine increase after infection (Fig. 3A) (Danlos et al. 2021; Thomas et al. 2020b). Glutamate and aspartate, derived from the Krebs cycle, are elevated in symptomatic patients (Ansone et al. 2021; Bruzzone et al. 2020; Caterino et al. 2021; Herrera-Van Oostdam et al. 2021; Jia et al. 2022; Karagiannis et al. 2022; Krishnan et al., 2021; Lawler et al. 2021; Lee et al. 2024; Lewis et al. 2022; Lodge et al. 2023; Ma et al. 2023; D. Shi et al. 2021; Whiley et al. 2024; Xiao et al. 2021), while other Krebs and urea cycle-related AAs are generally reduced (Albóniga et al. 2022; Ansone et al. 2021; Bruzzone et al. 2020; D’Alessandro et al. 2021; Giron et al. 2021; Jia et al. 2022; Karagiannis et al. 2022; Lee et al. 2024; Martínez-Gómez et al. 2022; Masoodi et al. 2022; Meoni et al. 2021; Páez-Franco et al. 2021; Thomas et al., 2020a, 2020b). Ornithine shows conflicting trends, with both increases and decreases reported (Fig. 3A). Tryptophan is consistently reduced (Albóniga et al. 2022; Escarcega et al. 2022; Essex et al. 2024; Herrera-Van Oostdam et al. 2021; Karagiannis et al. 2022; Lawler et al. 2021; Lee et al. 2024; Masoodi et al. 2022; Occelli et al. 2022; Saheb Sharif-Askari et al. 2022; Thomas et al. 2020b), while the kynurenine pathway is upregulated, with most of its metabolites increased (e.g., kynurenine and hydroxykynurenine), especially in severe cases (Dewulf et al. 2022; Essex et al. 2024; Herrera-Van Oostdam et al. 2021; Lawler et al. 2021; Xiao et al. 2021). An elevated kynurenine/tryptophan ratio suggests increased IDO1 activity. IDO1 inhibition in macaque peripheral blood mononuclear cells reduces the secretion of pro-inflammatory cytokines, highlighting the pathway’s role in SARS-CoV-2 inflammation (Xiao et al. 2021). In contrast, the serotonin pathway is suppressed, with decreased levels of 5-hydroxytryptophan, serotonin, and N-acetylserotonin (Fig. 3A) (Caterino et al. 2021; Escarcega et al. 2022; Essex et al. 2024; Lee et al. 2024; Saheb Sharif-Askari et al. 2022; Thomas et al., 2020b 2020; Xiao et al. 2021). Other essential AAs such as histidine, lysine, and threonine are reduced (Albóniga et al. 2022; Ansone et al. 2021; Bruzzone et al. 2020; D’Alessandro et al. 2021; Karagiannis et al. 2022; Lawler et al. 2021; Lee et al. 2024; Maeda et al. 2023; Masoodi et al. 2022; Páez-Franco et al. 2021; Saheb Sharif-Askari et al. 2022; Thomas et al., 2020b), while leucine and phenylalanine are also typically increased (Fig. 3A) (Albóniga et al. 2022; Ansone et al. 2021; Bruzzone et al. 2020; Caterino et al. 2021; Danlos et al. 2021; Dewulf et al. 2022; Escarcega et al. 2022; Herrera-Van Oostdam et al. 2021; Lawler et al. 2021; T. Li et al. 2021; Maeda et al. 2023; Martínez-Gómez et al. 2022; Meoni et al. 2021; D. Shi et al. 2021; Thomas et al., 2020b; J. Wu et al. 2021). SARS-CoV-2 infection leads to a decrease in most AA levels, which an increase in AA catabolism could explain. Many metabolites from the kynurenine pathway increase after infection (Fig. 3A), highlighting the immunomodulatory impact of SARS-CoV-2. Influenza virus infection reduces amino acid levels while promoting the tryptophan/kynurenine pathway IV infection is associated with a general decrease in host AA levels, particularly those derived from glycolysis and the Krebs cycle. Glycine and serine levels decline following infection (Cui et al., 2016; Lee et al., 2024; Ohno et al., 2020), with serine specifically reduced in IV-infected patients compared to those with bacterial pneumonia, suggesting virus-specific effects on serine metabolism (Banoei et al., 2017). Methionine, an essential AA, also decreases post-infection (Cui et al., 2016; Ohno et al., 2020), possibly reflecting increased utilization or a shift toward pyruvate and lactate production (Fig. 3B). Krebs cycle-related AAs glutamate, glutamine, alanine, asparagine, and proline are reduced (Beale et al. 2019; Izquierdo-Garcia et al. 2018; Lee et al. 2024; Liempd et al. 2021; Ohno et al. 2020; X. Shi et al. 2024). Notably, lower glutamine and alanine levels correlate with disease severity, being more pronounced in acute respiratory distress syndrome patients (Izquierdo-Garcia et al. 2018). Aspartate shows variable changes increased in patient samples but decreased in mouse models (Banoei et al. 2017; Ohno et al. 2020). In the urea cycle, ornithine and urea levels increase, while citrulline and arginine decrease (Fig. 3B) (Lee et al. 2024; Liempd et al. 2021; Ohno et al. 2020; X. Shi et al. 2024). IV infection also enhances the kynurenine pathway. Tryptophan and kynurenine levels increase (Chandler et al., 2016; Cho et al., 2021; Cui et al., 2016, 2017; Gaelings et al., 2017; Lee et al., 2024), with a higher kynurenine-to-tryptophan ratio linked to worse outcomes (Pizzini et al., 2019). This pathway is activated by interferon-induced IDO1 expression, although viral proteins like NS1 can suppress it (Gaelings et al., 2017), reflecting a virus strategy to modulate host immunity. Meanwhile, serotonin and its precursor 5-hydroxytryptophan are reduced in human and mouse models (Chandler et al., 2016; Lee et al., 2024), suggesting a diversion of tryptophan away from the serotonin/melatonin pathway (Fig. 3B). While some essential AAs, such as valine, isoleucine, and phenylalanine increase (Banoei et al., 2017; Cui et al., 2016; Lee et al., 2024; Ohno et al., 2020), others including leucine, histidine, lysine or threonine are decreased (Banoei et al., 2017; Cui et al., 2016, 2017; Lee et al., 2024; Liempd et al., 2021; Ohno et al., 2020). Interestingly, leucine levels decline in human serum but increase in mice, highlighting model-specific differences (Fig. 3B) (Cui et al., 2016). Overall, IV infection causes widespread AA depletion, potentially due to increased catabolism that supports viral replication while simultaneously activating the kynurenine pathway, possibly contributing to inflammation modulation (Fig. 3B). SARS-CoV-2 and influenza virus infections reduces many amino acid levels and induce an increase in most kynurenine pathway compounds Viral infections lead to a high consumption of AA to produce viral proteins, which could explain the decrease in most AA induced by a SARS-CoV-2 or IV infection. Moreover, tryptophan is metabolized by IDO1 into kynurenine, as evidence by an increased kynurenine/tryptophan ratio observed in both SARS-CoV-2 and IV infections, reflecting the activation of inflammatory and immunomodulatory pathways induced by these viruses. Hijacking nucleotide pools for genome synthesis Nucleotides regrouping purines, pyrimidines and their derivates are biomolecules that act as building blocks for both DNA and RNA, but they also serve other purposes like providing energy to cells, participating in signalisation, or as glycosylated biomolecule precursors (Liu et al., 2022; Vincenzetti et al., 2016). Purine biosynthesis involves two pathways: the salvage pathway, which recycles components from degraded RNA and DNA to form new nucleotides (Liu et al., 2022), and the de novo pathway, where the “purinosome” enzyme complex located near the mitochondria synthesizes inosine monophosphate (IMP) from ribose 5-phosphate, leading to adenosine monophosphate (AMP), and guanosine monophosphate (GMP) (Liu et al., 2022). Similarly, pyrimidines are synthesized via the salvage or the de novo pathways. The salvage pathway recycles pyrimidine bases into di- or triphosphate nucleotides (Vincenzetti et al., 2016), while the de novo pathway converts carbamoyl phosphate and aspartate into uridine- and cytosine-phosphate (Vincenzetti et al., 2016) (Fig. 2). Purines and pyrimidines comprise the genomes of both RNA and DNA viruses and play a crucial role in viral replication. Many viruses increase glycolysis and the pentose phosphate pathway, leading to an increase in nucleotide biosynthesis (Kleinehr et al., 2021; Sanchez & Lagunoff, 2015). Moreover, pyrimidine metabolism is implicated in the synthesis of uridine diphosphate sugars, which are used in the biosynthesis of viral glycoproteins, including those of Human cytomegalovirus (Sanchez & Lagunoff, 2015). The metabolic shift during a SARS-CoV-2 infection induces an increase in nucleotide pathways, including de novo biosynthesis SARS-CoV-2 infection leads to an accumulation of several metabolites implicated in the early steps of the purine de novo biosynthesis pathway, while IMP levels remain largely unchanged (Xiao et al. 2021; Zhang et al. 2021). In contrast, downstream IMP-derived nucleotides, such as AMP, adenosine diphosphate (ADP), ATP, GMP and guanosine triphosphate (GTP) are significantly elevated (Gassen et al. 2021; Ma et al. 2023; Maeda et al. 2023; Saheb Sharif-Askari et al. 2022; Thomas et al., 2020b; Xiao et al. 2021), suggesting an overall upregulation of purine de novo biosynthesis pathway during SARS-CoV-2 infection. Metabolites from the salvage pathway, namely adenine, inosine, hypoxanthine, and xanthine, have increased levels after the infection (Caterino et al. 2021; Saheb Sharif-Askari et al. 2022; Thomas et al., 2020b; Xiao et al. 2021), whereas guanosine, which is decreased (Saheb Sharif-Askari et al. 2022; Xiao et al. 2021). Thus, both the de novo and salvage pathways of purine metabolism appear upregulated during SARS-CoV-2 infection (Fig. 3A). According to Zhang et al., the increase in the de novo pathway and the stability in IMP levels suggest a balance between synthesis and consumption of purines after infection (Zhang et al. 2021). Interestingly, SARS-CoV-2 may have direct effects on purine metabolism as Nsp14 can interact with the inosine-5’-monophosphate dehydrogenase 2 (IMPDH2), an enzyme involved in the de novo synthesis of guanine (Gordon et al. 2020). Some metabolites of the de novo pyrimidine biosynthesis pathway, namely carbamoyl aspartate, deoxythymidine triphosphate, uridine triphosphate, and cytosine triphosphate (CTP), have increased levels after SARS-CoV-2 infection (Gassen et al. 2021; Saheb Sharif-Askari et al. 2022). Conversely, carbamoyl phosphate at the beginning of the pathway is decreased during infection (D. Wu et al. 2020). Metabolites from the salvage pathway, such as cytidine, cytosine, and thymidine, are also increased after the infection (Chen et al. 2021; T. Li et al. 2021; Xiao et al. 2021). The decrease in dihydrouracil and the increase in its products, carbamoyl alanine and β-alanine (Byeon et al. 2022; Caterino et al. 2021; Chen et al. 2021; D. Wu et al. 2020), which are both uracil breakdown products, suggest that this pathway is also increased during this viral infection. Hence, pyrimidine metabolism seems upregulated through its de novo, salvage, and breakdown pathways (Fig. 3A). Interestingly, the inhibition of dihydroorotate dehydrogenase (DHODH), one of the pyrimidine rate-limiting enzymes in this pathway, reduces the viral load in Vero cells, suggesting that the de novo pyrimidine pathway is essential for SARS-CoV-2 replication (Luban et al. 2021). Influenza virus infection induces an increase in the metabolites from nucleotide salvage pathways A few metabolites from the de novo purine biosynthesis pathway have been described as increased during IV infection, namely ADP, ATP, guanosine diphosphate (GDP), and deoxuguanosine (Cui et al. 2016; Ledderose et al. 2024; Ritter et al. 2010; X. Shi et al. 2024). On the other hand, a large part of the salvage pathway, including guanosine and other metabolites from inosine to xanthine, is increased during infection (Akaike et al. 1990; Chandler et al. 2016; Cui et al. 2016, 2017; Ohno et al. 2020; X. Shi et al. 2024). Conversely, adenine is decreased after IV infection (Chandler et al. 2016; Ma et al. 2023). Therefore, metabolomics studies suggest that IV infection disrupts purine metabolism, a finding supported by the upregulation of enzymes involved in these pathways (Fig. 3B) (Kroeker et al. 2013). Moreover, some of that disruption may be direct as the IV can interact through its NP protein with the phosphoribosyl-aminoimidazole carboxylase and phosphoribosylaminoimidazole succinocarboxamide synthase (Generous et al. 2014). In the pyrimidine de novo pathway, only uridine monophosphate (UMP), CTP, and uracil are observed as increased (Cui et al., 2016; Ritter et al., 2010), while uridine diphosphate and cytidine monophosphate (CMP) are shown as decreased (Cui et al., 2016). Disruptions of only two metabolites of the salvage pathway have been identified: cytidine and uridine, with increased levels observed during IV infection (Chandler et al., 2016; Cui et al., 2016). Because metabolites from the late de novo and the salvage pathway are increased, pyrimidine metabolism seems up-regulated after IV infection. Interestingly, it has been demonstrated that inhibiting DHODH activity affects the growth of the virus, emphasizing the critical role of pyrimidine metabolism in influenza infection (Sibille et al., 2022). IV infection leads to a quite unclear de novo purine pathway disruption. However, some de novo and salvage pathways metabolites seem up-regulated during infection. Similarly to purines, the host response concerning pyrimidine metabolites remains unclear, but studies suggest that the de novo pathway is reduced while the salvage pathway increases after infection (Fig. 3B). Nevertheless, the increased activity of key enzymes and the reduction in virus growth following DHODH inhibition suggest that those pathways are essential in IV replication. SARS-CoV-2 and influenza virus infections induce increase in metabolite levels of de novo and salvage pathways of both purine and pyrimidine metabolism, with a stronger impact for SARS-CoV-2 SARS-CoV-2 and IV infections lead to an increase in the number of purine and pyrimidine metabolites, which can be used for their genome replication and mRNA production. Interestingly, a higher amount of purine salvage metabolites is increased by a SARS-CoV-2 infection, while an IV infection increases a larger number of pyrimidine salvage metabolites. SARS-CoV-2 appears to induce a more substantial disruption of the de novo pathways. Both viruses directly disrupt nucleotide metabolism, as some viral proteins can bind key nucleotide enzymes. Discussion Here, we provide an integrated comparison of the metabolic reprogramming induced by SARS-CoV-2 and influenza virus, highlighting both shared and virus-specific alterations. As Viruses are known to reprogram host metabolism during infection (Thaker et al., 2019), both SARS-CoV-2 and IV are no exception. A subset of the host metabolic response is shared between these respiratory viruses, including alterations in end-products of glycolysis, early intermediates of the Krebs cycle, several AA, key metabolites of the kynurenine and serotonin pathways and purine metabolism compounds (Fig. 3A, B; Table 1). These similarities point to a conserved metabolic signature of respiratory viral infections. Conversely, virus-specific metabolic responses have also been identified. These include distinct alterations in Krebs cycle intermediates, selective AA such as glutamate or tryptophan, purine de novo biosynthesis pathway compounds and pyrimidine metabolism (Fig. 3A, B; Table 1). Viral proteins contribute to these disruptions. Indeed, it is known that SARS-CoV-2 spike protein activates the Akt pathway (Al-Qahtani et al., 2022), while IV NS1 induces the PI3K/Akt/mTOR pathway (Dai et al., 2011). Interestingly, beyond the nature of the disrupted pathways, the intensity of the metabolic response also differs. While both viruses induce similar alteration in glycolysis or amino acids metabolism, SARS-CoV-2 elicits a more pronounced response (Lee et al., 2024). Table 1Overview of SARS-CoV-2 and influenza virus impact on host central metabolismThe impacts of SARS-CoV-2 and influenza on (A) Glycolysis, (B) Krebs cycle, (C) AA metabolism, (D) Nucleotide metabolism, are compared. Red indicates increases in metabolite levels, while blue indicates decreases in metabolite levels compared to non-infected Overview of SARS-CoV-2 and influenza virus impact on host central metabolism The impacts of SARS-CoV-2 and influenza on (A) Glycolysis, (B) Krebs cycle, (C) AA metabolism, (D) Nucleotide metabolism, are compared. Red indicates increases in metabolite levels, while blue indicates decreases in metabolite levels compared to non-infected This review focus on specific pathways of the metabolism, but other pathways are also disrupted after SARS-CoV-2 or influenza virus infection. For example, numbers of compounds of the tryptophan to indole pathway linked to microbiota are decreased by both viral infections. This include indole-3-acetate and indole-3-propionate which have anti-inflammatory and anti-oxidative activities (Al-Shalan et al. 2023; Cui et al. 2016; Escarcega et al. 2022; Essex et al. 2024; Heumel et al. 2024; Lawler et al. 2021; Lee et al. 2024; Masoodi et al. 2022). Polyamines which are also linked to microbiota and notably spermine and spermidine have elevated levels during SARS-CoV-2 and influenza virus infection (Heumel et al. 2024; Lee et al. 2024; Thomas et al., 2020b). Interestingly, a lack of polyamine impairs SARS-CoV-2 and influenza virus infections, and more specifically SARS-CoV-2 cellular attachment (Firpo et al. 2021; Jo et al. 2024). Conversely, an excess of polyamines also disturb viral infection by suppressing SARS-CoV-2 ORF3a activity probably through its cytosolic and transmembrane domains (Boonamnaj et al. 2023), Those metabolic disruptions imply that viral infections affect the whole metabolism, and even the microbiota related one. Although a consensus has emerged around certain disrupted metabolites, discrepancies remain across studies. These inconsistencies likely stem from the diversity of experimental models, sample types (human blood, animal model, cells, …) (Pinto et al., 2023; Ramos et al., 2022), and analytical platforms employed (Table 2). Advances in metabolomics, including high-resolution instrumentation, machine learning, molecular networking, and improved spectral annotation, are progressively enhancing data quality and interpretability (Ebbels et al., 2023). Table 2Disruption of Krebs cycle metabolites following SARS-CoV-2 or IV infection, as reported in the literatureMetaboliteVirusSample typeMethodSeverityCohort confusing factorsReferenceOxaloacetateSARS-CoV-2 Human saliva LC-MS Severe None Saheb Sharif-Askari et al., 2022 Human plasma LC-MS Asymptomatic, mild, moderate, severe None Saheb Sharif-Askari et al., 2022 CitrateSARS-CoV-2 Human serum NMR Symptomatic Age, smoker Bruzzone et al., 2020 Human plasma LC-MS Moderate, severe Age Herrera-Van Oostdam et al., 2021 Human plasma LC-MS Moderate, severe Comorbidities Lee et al., 2024 Human plasma CE-MS Mild, moderate, severe Age Sánchez-García et al., 2021 Human plasma NMR Positive Comorbidities Meoni et al., 2021 Human serum LC-MS Severe None Escarcega et al., 2022 Human serum GC-MS Mild, severe None D. Shi et al. 2021 Human serum GC-MS Severe Age, BMI, comorbidities Martínez-Reyes & Chandel, 2020 Mice serum LC-MS Severe None Giron et al., 2021 Influenza Mice serum LC-MS Mild None Banoei et al., 2017 MDCK cells LC-MS NA None Cui et al., 2017 Human plasma LC-MS Severe Comorbidities Lee et al., 2024 Human plasma NMR Severe BMI Liempd et al., 2021 Human serum LC-MS Moderate None S. Li et al. 2023 Mice serum LC-MS Moderate, severe None Beale et al., 2021 Ferret nasal wash samples GC-MS Mild, moderate, recovery None Fabbrizi et al., 2023 IsocitrateSARS-CoV-2 Human serum LC-MS Severe None Escarcega et al., 2022 Influenza MDCK cells LC-MS NA None Cui et al., 2017 Alpha-ketoglutarateSARS-CoV-2 Human plasma LC-MS Positive None Páez-Franco et al., 2021 Human plasma LC-MS Moderate, severe Comorbidities Lee et al., 2024 Human serum LC-MS IL-6 low, IL-6 high Sex Thomas et al., 2020b Human serum LC-MS Severe Age Jia et al., 2022 Human serum LC-MS Severe None Escarcega et al., 2022 Human serum GC-MS Mild/moderate Age, BMI, comorbidities Martínez-Reyes & Chandel, 2020 Human red blood cells LC-MS Positive None Thomas et al., 2020a Calu-3 cells extracellular media LC-MS NA None Kroeker et al., 2013 Influenza MDCK cells LC-MS NA None Cui et al., 2017 Human plasma NMR Deceased vs. survivor BMI Liempd et al., 2021 Mice serum LC-MS Moderate, severe None Beale et al., 2021 Ferret nasal wash samples GC-MS Mild, moderate None Fabbrizi et al., 2023 SuccinateSARS-CoV-2 Human plasma LC-MS Moderate, severe BMI, comorbiditoes Barberis et al., 2020 Human plasma LC-MS Moderate, severe Comorbidities Lee et al., 2024 Human plasma GC-MS Mild, moderate, severe None Albóniga et al., 2022 Human serum LC-MS Moderate Sex Caterino et al., 2021 Human serum GC-MS Mild, severe None D. Shi et al. 2021 Human serum NMR Symptomatic Age, smoker Bruzzone et al., 2020 Human saliva LC-MS Severe None Saheb Sharif-Askari et al., 2022 Calu-3 cells extracellular media LC-MS NA None Kroeker et al., 2013 Human plasma LC-MS Asymptomatic, mild, moderate, severe None Saheb Sharif-Askari et al., 2022 Influenza Mice serum LC-MS Mild None Beale et al., 2021 Mice plasma LC-MS Moderate, severe, recovery None Al-Qahtani et al., 2022 Mice serum LC-MS Severe None Beale et al., 2021 Ferret nasal wash samples GC-MS Mild, moderate None Fabbrizi et al., 2023 MDCK cells LC-MS NA None Akaike et al., 1990 FumarateSARS-CoV-2 Human plasma LC-MS Moderate, severe Comorbidities Lee et al., 2024 Human red blood cells LC-MS Positive None Thomas et al., 2020a Calu-3 cells extracellular media LC-MS NA None Kroeker et al., 2013 Mice serum LC-MS Severe None Giron et al., 2021 Influenza MDCK cells LC-MS NA None Cui et al., 2017 Mice serum LC-MS Severe None Beale et al., 2021 MalateSARS-CoV-2 Human serum LC-MS Severe None Escarcega et al., 2022 Human serum LC-MS Severe, recovery Age Jia et al., 2022 Human serum GC-MS Mild/moderate Age, BMI, comorbidities Martínez-Reyes & Chandel, 2020 Human saliva LC-MS Severe None Saheb Sharif-Askari et al., 2022 Calu-3 cells extracellular media LC-MS NA None Kroeker et al., 2013 Human plasma LC-MS Mild, severe, deceased Age Vincenzetti et al., 2016 Mice serum LC-MS Severe None Giron et al., 2021 Influenza MDCK cells LC-MS NA None Cui et al., 2017 Mice serum LC-MS Severe None Beale et al., 2021 References in Bold indicate increases in metabolite levels, while those in Italic indicate decreases in metabolite levels compared to non-infected.LC-MS liquid chromatography–mass spectrometry; NMR nuclear magnetic resonance; CE-MS capillary electrophoresis–mass spectrometry; GC-MS gas chromatography–mass spectrometry; NA not assessed; BMI body mass index Disruption of Krebs cycle metabolites following SARS-CoV-2 or IV infection, as reported in the literature References in Bold indicate increases in metabolite levels, while those in Italic indicate decreases in metabolite levels compared to non-infected. LC-MS liquid chromatography–mass spectrometry; NMR nuclear magnetic resonance; CE-MS capillary electrophoresis–mass spectrometry; GC-MS gas chromatography–mass spectrometry; NA not assessed; BMI body mass index A limited number of studies have directly compared the effects of SARS-CoV-2 and IV infection on the host’s metabolic response, making it difficult to compare the metabolic responses induced by these two viruses. Comparative studies on relevant and well-controlled models are needed to identify a global metabolic response that is independent of the variability associated with the multiple methods and models found in the literature. Furthermore, such studies may permit deciphering the part of the metabolic response specific to either SARS-CoV-2 or IV infection, and the part shared by all respiratory viral infections. Furthermore, the mechanisms underlying these metabolic perturbations remain to be fully elucidated. A deeper understanding of virus-induced metabolic disruptions and their associated mechanisms may lead to the identification of new biomarkers for detecting viral infections, predicting severity scores, and targeting antiviral therapies. In the context of future precision medicine, the metabolic profiling of viral infections may become a cornerstone for individualized patient care. Instead of relying solely on the traditional viral–bacterial dichotomy, future diagnostic and therapeutic strategies could be tailored to the specific virus involved. Such virus-specific metabolic signatures could inform not only the diagnosis but also the prognosis and therapeutic decisions, enabling clinicians to stratify patients based on their metabolic response to a given pathogen. This approach would enable the development of targeted antiviral therapies, personalized nutritional and metabolic interventions, and more accurate severity prediction models. Ultimately, integrating virus-specific metabolic fingerprints into clinical workflows could pave the way for a more nuanced and effective management of infectious diseases. Abbreviations Amino acid Angiotensin-converting enzyme 2 Adenosine diphosphate RAC serine/threonine-protein kinase Adenosine monophosphate Adenosine triphosphate Body mass index Capillary electrophoresis–mass spectrometry Cytidine monophosphate Acetyl-coenzyme A Coronavirus disease 2019 Cytosine triphosphate Dihydroorotate dehydrogenase Deoxyribonucleic acid Endoplasmic-reticulum–Golgi intermediate compartment Extracellular signal-regulated kinases Gas chromatography–mass spectrometry Guanosine diphosphate Guanosine monophosphate Guanosine triphosphate Hemagglutinin Hypoxia-inducible factor 1 Indoleamine 2,3-dioxygenase 1 Inosine monophosphate Inosine-5’-monophosphate dehydrogenase 2 Influenza virus Liquid chromatography–mass spectrometry Mitogen-activated protein kinase Dual specificity mitogen-activated protein kinase kinase Messenger RNA Mammalian target of rapamycin complex 1 Not assessed Nicotinamide adenine dinucleotide Nuclear magnetic resonance Non-structural protein Origin of replication 3a Phosphatidylinositol 3-kinase Rapidly accelerated fibrosarcoma Ribonucleic acid Sirtuin Transmembrane protease serine 2 Uridine monophosphate Viral ribonucleoprotein Author contributions Conceptualization: CT, OT, ALG; Funding acquisition: OT, ALG; Supervision: OT, ALG; Writing - original draft: CT; Writing - review & editing: CT, OT, ALG. Funding This work was supported by FINOVI, The Air Liquide Foundation and Foundation Université Grenoble Alpes (IDIVIA-MET Project). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Conflict of interest The authors declare that they have no competing interests. Ethical approval and consent to participate The authors declare that ethical approval was not required. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Olivier Terrier and Audrey Le Gouellec contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.